Gossamer Bio Announces Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 11c
November 12, 2019 4:39 PM ESTGossamer Bio Inc. (NASDAQ: GOSS) reported Q3 EPS of ($0.80), $0.11 worse than the analyst estimate of ($0.69).
Since the beginning of the third quarter, we have realized substantial progress advancing our diverse pipeline of four clinical-stage programs, said Sheila Gujrathi, M.D., Co-Founder and Chief Executive... More
